diaDexus Release: New Data Published In An American Heart Association Journal Shows That Lipoprotein-Associated Phospholipase A2 Independently Adds To The Diagnostic Accuracy Of Traditional Risk Assessment For Future Cardiovascular Events

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--June 26, 2006--diaDexus today announced that new data published in the American Heart Association’s journal Arteriosclerosis, Thrombosis, and Vascular Biology showed that coronary heart disease (CHD) patients with the highest levels of the enzyme Lp-PLA2 were more than twice as likely to have a recurrent cardiovascular event, whereas 95% of the patients with the lowest levels of the enzyme remained event-free over four years of follow up. The study was led by Dr. Wolfgang Koenig, Department of Internal Medicine II -- Cardiology, University of Ulm Medical Center, Ulm, Germany.